Literature DB >> 15202696

Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine.

Paul M Gahlinger1.   

Abstract

Club drugs are substances commonly used at nightclubs, music festivals, raves, and dance parties to enhance social intimacy and sensory stimulation. The most widely used club drugs are 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy; gamma-hydroxybutyrate (GHB); flunitrazepam (Rohypnol); and ketamine (Ketalar). These drugs are popular because of their low cost and convenient distribution as small pills, powders, or liquids. Club drugs usually are taken orally and may be taken in combination with each other, with alcohol, or with other drugs. Club drugs often are adulterated or misrepresented. Any club drug overdose should therefore be suspected as polydrug use with the actual substance and dose unknown. Persons who have adverse reactions to these club drugs are likely to consult a family physician. Toxicologic screening generally is not available for club drugs. The primary management is supportive care, with symptomatic control of excess central nervous system stimulation or depression. There are no specific antidotes except for flunitrazepam, a benzodiazepine that responds to flumazenil. Special care must be taken for immediate control of hyperthermia, hypertension, rhabdomyolysis, and serotonin syndrome. Severe drug reactions can occur even with a small dose and may require critical care. Club drug over-dose usually resolves with full recovery within seven hours. Education of the patient and family is essential.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15202696

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  27 in total

1.  ConceptMetab: exploring relationships among metabolite sets to identify links among biomedical concepts.

Authors:  Raymond G Cavalcante; Snehal Patil; Terry E Weymouth; Kestutis G Bendinskas; Alla Karnovsky; Maureen A Sartor
Journal:  Bioinformatics       Date:  2016-01-21       Impact factor: 6.937

2.  Poly-Drug Use among Ecstasy Users: Separate, Synergistic, and Indiscriminate Patterns.

Authors:  M Boeri; C Sterk; M Bahora; K Elifson
Journal:  J Drug Issues       Date:  2008-04

3.  Reinforcing effectiveness of midazolam, ethanol, and sucrose: behavioral economic comparison of a mixture relative to its component solutions.

Authors:  E Andrew Townsend; Donna M Platt; James K Rowlett; Peter G Roma; Kevin B Freeman
Journal:  Behav Pharmacol       Date:  2017-08       Impact factor: 2.293

4.  Investigation of some biologically relevant redox reactions using electrochemical mass spectrometry interfaced by desorption electrospray ionization.

Authors:  Mei Lu; Chloe Wolff; Weidong Cui; Hao Chen
Journal:  Anal Bioanal Chem       Date:  2012-01-12       Impact factor: 4.142

Review 5.  Reducing HIV Risks in the Places Where People Drink: Prevention Interventions in Alcohol Venues.

Authors:  Eileen V Pitpitan; Seth C Kalichman
Journal:  AIDS Behav       Date:  2016-01

6.  Circumstances of initiation into new-type drug use among adults in Shanghai: are there differences by types of first new-type drug used?

Authors:  Yingying Ding; Na He; Roger Detels
Journal:  Drug Alcohol Depend       Date:  2013-01-09       Impact factor: 4.492

7.  Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, γ-hydroxybutyric acid.

Authors:  Nisha Vijay; Marilyn E Morris
Journal:  J Pharm Sci       Date:  2014-08-29       Impact factor: 3.534

8.  Treatment of disorders of hypersomnolence.

Authors:  Olufemi Adenuga; Hrayr Attarian
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

9.  Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study.

Authors:  Judith C Barker; Shana L Harris; Jo E Dyer
Journal:  J Psychoactive Drugs       Date:  2007-06

10.  Expression of neuronal trace amine-associated receptor (Taar) mRNAs in leukocytes.

Authors:  Daniel A Nelson; Melanie D Tolbert; Sam J Singh; Kenneth L Bost
Journal:  J Neuroimmunol       Date:  2007-09-27       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.